A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

Megestrol acetate (MA) is a synthetic progestin with reported activity in both hormone‐sensitive and hormone‐refractory prostate carcinoma (HRPC). Based on limited data suggesting a possible dose‐response effect, a trial was initiated to compare standard versus moderately high dose MA in HRPC.

[1]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Heitjan,et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Budman,et al.  Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  N. Dawson.  Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Sloan,et al.  Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes , 1998, Cancer.

[6]  S. Litwin,et al.  Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Smith,et al.  Megestrol acetate in the treatment of hormone refractory prostate cancer. , 1997, American journal of clinical oncology.

[8]  E. Small,et al.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Leinung,et al.  Induction of Adrenal Suppression by Megestrol Acetate in Patients with AIDS , 1995, Annals of Internal Medicine.

[11]  N. Dawson,et al.  Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. , 1995, The Journal of urology.

[12]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[13]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[14]  K. Pienta,et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[16]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Holmberg,et al.  High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. , 1991, British journal of urology.

[18]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[19]  T. Therneau,et al.  A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate , 1990, Cancer.

[20]  J. Veldscholte,et al.  Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. , 1990, Biochimica et biophysica acta.

[21]  I. Sasagawa,et al.  Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer. , 1990, British journal of urology.

[22]  P. Macleod,et al.  Megestrol acetate in relapsed carcinoma of prostate. , 1990, British journal of urology.

[23]  N. Olea,et al.  The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. , 1990, Endocrinology.

[24]  L. Klotz,et al.  Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. , 1988, Seminars in oncology.

[25]  D. Raghavan,et al.  Phase II study of megestrol acetate for metastatic carcinoma of the prostate. , 1987, British journal of urology.

[26]  S. Fosså,et al.  Flare reaction during the initial treatment period with medroxyprogesterone acetate in patients with hormone-resistant prostatic cancer. , 1986, European urology.

[27]  R. Wittes,et al.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Wolter,et al.  Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. , 1985, Seminars in oncology.

[29]  Elder Js,et al.  Ongoing phase II & III studies of the USA National Prostatic Cancer Project. , 1985 .

[30]  J. Johansson,et al.  High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma. , 1985, European urology.

[31]  S. Fosså,et al.  High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study. , 1985, European Urology.

[32]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[33]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[34]  S. Yen,et al.  Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. , 1981, The Journal of clinical endocrinology and metabolism.

[35]  N. Slack,et al.  Response criteria for the prostate of the USA national prostatic cancer project , 1980, The Prostate.

[36]  S. Yen,et al.  Treatment of advanced cancer of prostate with megestrol acetate. , 1978, Urology.

[37]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[38]  S. Yen,et al.  Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. , 1976, The Journal of clinical endocrinology and metabolism.

[39]  Blackard Ce.  The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. , 1975 .

[40]  A. Ayala,et al.  Megestrol acetate for treatment of advanced carcinoma of the prostate , 1975, Journal of surgical oncology.

[41]  C E Blackard,et al.  The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. , 1975, Cancer chemotherapy reports.

[42]  D. G. Anderson.  The possible mechanisms of action of progestins on endometrial adenocarcinoma. , 1972, American journal of obstetrics and gynecology.

[43]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[44]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .